



Patent Docket P1994R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Group Art Unit: Not Assigned

Clark et al.

Examiner: Not Assigned

Serial No.: 10/533.520

Eta. m. ion i to i 7 issignou

3eliai 140.. 10/333,3

Confirmation No: Not Assigned

Filed: 28 April 2005

CUSTOMER NO: 09157

For: COMPOSITIONS AND METHODS
FOR THE TREATMENT OF IMMUNE-

CERTIFICATE OF MAILING hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail

RELATED DISEASES

Santambar / 20

Bailey Lee

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[x] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1,491, or
- · before the mailing of the first Office action on the ments; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

[] 37 CFR §1.97(c)

 by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below

[] 37 CFR §1.97(d)

 offer the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cifed in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR § 1.98(a) [2] (iii)]. See Final Rule 1287 OG (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. 60/429,069, filed 26 November 2002 and benefit from the prior application is claimed in this application under 35 U.S.C. § 120. However, copies of any cited

Serial No.: 10/533,520 Filing Date: 28 April 2005

Page 3

document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

[x] not given

[] given for each listed item

[] given for only non-English language listed item(s) [Required]

 in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTE@H

Pavid A. Carpenter Reg. No. 45,945 Telephone No. (650)

Date: September (, 2005

							S	Sheet 1 of 1	
FORM	PTO.	1449		U.S. Dept. of Commerce	Atty Docket No.			Serial No.	
1 01 1141		1440		Patent and Trademark Office	P1994	R1	1	0/533,520	
			/	۷.	Appli	cant .			
LIST	OF DI	SCLOSURES CITED E	BY APPLICANT S	EP 0 8 2005 E)		ry Sarah et			
(U	se sev	SCLOSURES CITED E reral sheets if necessar	y) (a	(بير	Filing Date 28 Apr 2005			Group Not Assigned	
			(E)	MAN AND AND AND AND AND AND AND AND AND A		Apr 2005		oc Assigned	
				THE PATENT DOCUMENTS	s —			Torontofor	
Examiner nitials		Document Number	Date	Country		Class	Subclas	Translation s Yes No	
/ECK/	1	WO 01/75166 A2	11.10.01	PCT					
				OSURES (Including Author, Title, Date,					
/ECK/	2	(Jun 1997)	ison, "Co-Stimu	lation in T Cell Responses" <u>Curr</u>	ent Op:	inion in Ir	mmunolog	y 9(3):396-404	
1	3	Coligan et al,, Sons, Inc., Chap	Proliferative ter 3.12, Vol.	Assays for T Cell Function" <u>Curr</u> 1 (1991)	ent Pro	otocols in	Immunol	ogy, John Wiley &	
\top	4	Joints and Improves Clinical Disease* Immunology 88:569-576 (1996) Jenkins, M.K., "The ups and downs of T cell costimulation" Immunity 1(6):443-446 (Sep 1994)							
	5								
	6	June, C. H. et a	1., "The B7 and	CD28 Receptor Families Tmmunol	cgy To	day 15(7):	321-331	(Jul 1994)	
	7	Linsey, P.S. et al., -"The role of the CD28 receptor during T cell responses to antigen"- <u>Annu Rev</u> <u>Immunol.</u> 11:191-212 (1993)							
+	8			ned immunodeficiency mouse and heath. 146(3):580-588 (Mar 1995)	numan p	soriatic s	kin chim	meras. Validation	
	2	Schon, M. P. et a 3(2):183-188 (Fel		oriasis-like disorder induced by	naive	CD4+ T ce	lls" Nat	. Med.	
1/	10	Schwartz R., "Comproduction and in	stimulation of	T lymphocytes: the role of CD28, cell 71(7):1065-1068 (Dec 24, 199	CTLA-	4, and B7/1	BB1 in i	interleukin-2	
*									
			_						
				·					
Examine	r /E	lizabeth C. Kemm	erer/	C	ate Cons	sidered 06/	18/2009		
*Examir	ner: In	nitial if reference consider	dered, whether or r sidered. Include co	not citation is in conformance with MPEP opy of this form with next communication	609; dra to applic	aw line through	gh citation)	